In a 65-year-old woman with newly diagnosed diabetes who has been started on metformin and now has an HbA1c of 55 mmol/mol (5.5 %), when should the HbA1c be repeated and the medication reviewed?

HbA1c Monitoring After Metformin Initiation

Repeat HbA1c in 3 months to assess treatment response and determine if medication adjustment is needed. 1, 2, 3

Rationale for 3-Month Follow-up

The most recent guidelines consistently recommend reassessing HbA1c approximately 3 months after initiating or modifying glucose-lowering therapy 1, 2, 4, 3. This timeframe allows sufficient time for:

• Metformin to reach steady-state effectiveness – The medication achieves stable plasma concentrations within 24-48 hours, but full glycemic effects require several weeks 5
• HbA1c to reflect the treatment period – HbA1c represents average glucose over the preceding 2-3 months, so a 3-month interval captures the treatment effect 1, 3
• Early identification of inadequate response – Delays in treatment intensification (therapeutic inertia) are associated with worse cardiovascular outcomes 6, 7

What to Do at 3 Months

If HbA1c remains at target (≤6.5-7.0% or 48-53 mmol/mol):

• Continue metformin monotherapy 2, 3
• Repeat HbA1c every 6 months if stable and at goal 8, 9
• Consider annual monitoring if HbA1c has been stable over several years 8

If HbA1c is above individualized target:

• Add a second agent immediately – Do not delay treatment intensification 1, 2, 3
• Choice of second agent depends on:
  • Presence of cardiovascular disease or risk factors → GLP-1 RA or SGLT2 inhibitor with proven CV benefit 2, 3, 10
  • Presence of heart failure → SGLT2 inhibitor 2, 3
  • Presence of chronic kidney disease → SGLT2 inhibitor or GLP-1 RA 2, 3
  • If no compelling comorbidities → Consider sulfonylurea, DPP-4 inhibitor, or GLP-1 RA based on patient factors 1, 2

Important Considerations for This Patient

Age-Specific Factors (65 years old):

• Target HbA1c of 7.0-7.5% (53-58 mmol/mol) is generally appropriate for healthy older adults 8, 9
• Less stringent targets (7.5-8.0% or 58-64 mmol/mol) may be appropriate if she has multiple comorbidities, limited life expectancy, or high hypoglycemia risk 8, 9
• More frequent monitoring of renal function is warranted in elderly patients on metformin 5

Current HbA1c of 55 mmol/mol (7.2%):

• This is slightly above the ideal target for most patients but may be acceptable depending on her overall health status 2, 9
• The magnitude of HbA1c reduction from baseline is prognostically important – larger initial reductions predict better cardiovascular outcomes 6, 11
• If her baseline HbA1c was significantly higher, achieving 55 mmol/mol represents good initial response and may not require immediate intensification 6, 11

Monitoring Schedule Going Forward

After the 3-month assessment:

• If at goal and stable → Every 6 months 8, 9
• If not at goal → Every 3 months until target achieved 1, 3
• If treatment intensified → Reassess in 3 months 1, 2, 3

Additional Monitoring Requirements:

• Vitamin B12 levels every 2-3 years on metformin 12, 5
• Annual hematologic parameters 5
• Renal function (eGFR) at least annually, more frequently if age ≥65 or declining kidney function 5

Common Pitfalls to Avoid

• Therapeutic inertia – Delaying treatment intensification when HbA1c is above target leads to worse outcomes 6, 7. The majority of patients with suboptimal control do not receive timely treatment adjustment 7
• Over-aggressive targets in older adults – HbA1c <6.5% (48 mmol/mol) is associated with increased mortality and hypoglycemia without clear benefit 8, 9
• Ignoring cardiovascular risk factors – In patients with established CVD or high risk, adding SGLT2 inhibitor or GLP-1 RA should be prioritized regardless of HbA1c 2, 3, 10
• Inadequate monitoring intervals – Waiting longer than 3-6 months to reassess allows prolonged hyperglycemia exposure 1, 4